<DOC>
	<DOC>NCT00774813</DOC>
	<brief_summary>The primary objectives of this Phase II study are to demonstrate the safety of Nexalin Therapy and to investigate the efficacy of Nexalin Therapy.</brief_summary>
	<brief_title>Nexalin Therapy for the Treatment of Depressive Symptoms</brief_title>
	<detailed_description>This randomized, double-blind, placebo-controlled, multi-center trial has 3 different treatment arms. Study Tools: - Hamilton Depression Rating Scale (HAM-D21) - Clinical Global Impressions (CGI) - Montgomery-Asberg Depression Rating Scale (MADRS) - Beck's Depression Inventory - Hamilton Anxiety Rating Scale (HAM-A) - Hospital Anxiety and Depression Scale (HADS)</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Diagnosed with mild to moderate depression episode, based on the HAMD21 Rating Scale (1013 = mild; 1417 = mild to moderate) Diagnosed with mild to moderate depression episode based on ICD10 Diagnostic Guidelines Is willing and able to spend 4 weeks as a hospital inpatient Is willing and able to return to the clinic during followup period A HAMD21 Rating Scale of &lt;10 or &gt;17 Diagnosed outside of mild to moderate depression episode range based on the ICD10 Diagnostic Guidelines Unable to complete washout interval without taking antidepressants or psychotropic medications Is pregnant or may be pregnant Sensitivity to electrodes and/or their conductive gels or adhesives Break in skin integrity at the areas of electrode placement Currently taking immune suppressing drugs or suspected use of narcotics Presence of any implanted electronic devices, cardiac stimulator, or pacemaker History of brain injury, including seizures, epilepsy, stroke, tumor of central nervous system, or hydrocephalus History of heart attacks, congestive heart failure, or uncontrolled hypertension History of schizophrenia or manicdepressive syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Depression</keyword>
	<keyword>Mild</keyword>
	<keyword>Moderate</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Kalaco Scientific, Inc.</keyword>
</DOC>